Evidence map›Paper›PMID 41960168›Full record

ArticleBioImpacts : BI2026

Exosomes: Redefining intercellular communication and the future of translational medicine.

Khosro Adibkia, Adel Mahmoudi Gharehbaba

Abstract readEditorial
In one paragraph

Article in BioImpacts : BI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Khosro AdibkiaResearch Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-1053-5557
Adel Mahmoudi GharehbabaResearch Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exosomes are promising extracellular vesicles for diagnostics, drug delivery, and regenerative medicine. While we have made significant strides in understanding exosomes biogenesis and cargo variability, the translation of exosome-based methods into clinical applications remains limited by challenges in manufacturing, standardization, and regulatory requirements. This editorial attempts to summarize the diverse field of exosome research including advances in isolation technologies and methodologies, omics characterization, and emerging bioengineering strategies that are elevating profile of exosomes as biomaterials for biomedical applications. We propose that exosomes are not just by-products of biological processes, but active information carriers with exceptional therapeutic potential. Therefore, the advancement of exosome methodologies in practice will ultimately alter the ways clinicians will evaluate diagnostic and therapeutic measures. We anticipate that the coming decades will establish a new, integrated framework for exosome science, one that harmonizes innovation, ethics, and cross-disciplinary collaboration to translate the promise of exosomes into tangible clinical reality.

Indexed as

Drug deliveryExosomesExtracellular vesiclesNanomedicinePrecision medicineTranslational biotechnology

Identifiers

PMID41960168
PMCPMC13058147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.